Hadassah

Placental Stem Cells Prove Successful in Bringing Little Girl to Recovery at Hadassah

Tuesday, May 15 2012

Using placental mesenchymal stem cells--which proved effective in pre-clinical trials--physicians at the Hadassah University Medical Center rescued the life of a seven-year-old Romanian girl whose two bone marrow transplants were not triggering the repair needed to save her life.

“B” was suffering from severe aplastic anemia, a disorder where the bone marrow does not produce sufficient new cells to replenish the blood. For the last 10 months, she had been hospitalized at Hadassah in critical condition. While her body accepted the two transplants from two different donors, the donated bone marrow was unsuccessful in getting her body to take over the replenishment process and produce new red blood cells. Prof. Reuven Or, head of the Sidney Weisner Department of Bone Marrow Transplantation and Cancer Immunology, decided to speak with Prof. Rafi Gorodetsky, Director of Hadassah’s Biotechnology and Radiobiology Laboratory in the Sharrett Institute of Oncology, who was conducting stem cell research sponsored by Pluristem Therapeutics, an Israeli bio-tech company which develops placental mesenchymal cells.  Prof. Gorodetsky's pre-clinical trial showed success in treating radiated mice with the Pluristem cells. (See ”Placental Cells Found to Have Potential to Mitigate Acute Radiation Syndrome,” in .)

After receiving the approvals of Hadassah's Helsinki Committee and Israel’s Ministry of Health, Hadassah’s physicians gave “B” two shots of the Pluristem cells, injecting them into her thigh muscle. The recovery was so significant that “B” was able to leave the hospital.

"This is a moment every physician and researcher waits for," says Prof. Or. "We now have a new tool and I always prefer to use biological substance over chemical components." Prof. Or cautions, however, that this is only one single case and 
the treatment still requires full scientific exploration and validation. Scientists at Pluristem and Prof. Or will now discuss “next steps” and how to widen the scope of their studies.

“Whatever happens next,” comments Ron Krumer, Director of Hadassah’s External Relations Department, “we can enjoy another story of life saving at Hadassah--a combination of the ingenuity of an Israeli biotech firm, Hadassah research, and Hadassah clinical excellence.”

Related Stories

alt_text

Monday, Jun 29 2020

COVID-19 Nursing Care Leads to Collaborative Research by Hadassah Nurses

With a little distance from the first phase of the COVID-19 pandemic, Hadassah Medical Organization nurse educator and critical care specialist Julie Benbenishty...

READ MORE ›
alt_text

Monday, Jun 29 2020

First Commercial Antibody Serum Given at Hadassah to COVID-19 Patient

The Hadassah Medical Organization worked with an ultra-Orthodox communal organization to collect antibody-rich plasma from recovered COVID-19 patients...

READ MORE ›
alt_text

Thursday, Jun 25 2020

A Family Legacy Continues at Hadassah Hospital Mount Scopus

When New Jersey-born book publicist Jessica Singer married Yehoshua Freud, a computational chemist last August...

READ MORE ›
alt_text

Wednesday, Jun 24 2020

“Failure to Thrive” Infant Diagnosed by Hadassah Specialists

Hannah Finkelstein* had nursed her three older children, all healthy and inquisitive youngsters. So when baby Leah, only 4 days old, was losing weight...

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Israel Travel

israeltravel@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More